MedTrace Logo

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

NCT03830827 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2019-11-29

No results posted yet for this study

Summary

This multicenter, double-blind, Randomized, parallel-group study in subjects with methamphetamine dependence was to assess the efficacy of MBRP combined with vortioxetine and MBRP alone on 24-week abstinence rates, improvement of cognition and depressive symptoms.

Conditions

Interventions

DRUG

Vortioxetine

8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks

Sponsors & Collaborators

  • Shenzhen Mental Health Center

    collaborator OTHER

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Sir Run Run Shaw Hospital

    lead OTHER

Principal Investigators

  • Yanhui Liao, MD · Sir Run Run Shaw Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-04-30
Completion
2021-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830827 on ClinicalTrials.gov